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ABSTRACT
Background: Streamlining the timing of treatments in
cystic fibrosis (CF) is important to optimise adherence
while ensuring efficacy. The optimal timing of
treatment with hypertonic saline (HTS) and airway
clearance techniques (ACT) is unknown.
Objectives: This study hypothesised that HTS before
ACT would be more effective than HTS during ACT as
measured by Lung Clearance Index (LCI).
Methods: Adults with CF providing written informed
consent were randomised to a crossover trial of HTS
before ACT or HTS during ACT on consecutive days.
ACT treatment consisted of Acapella Duet. Patients
completed LCI and spirometry at baseline and 90 min
post treatment. Mean difference (MD) and 95% CIs
were reported.
Results: 13 subjects completed the study (mean (SD)
age 33 (12) years, forced expiratory volume in 1second
% (FEV1%) predicted 51% (22), LCI (no. turnovers) 14
(4)). Comparing the two treatments (HTS before ACT
vs HTS during ACT), the change from baseline to
90 min post treatment in LCI (MD (95% CI) −0.02
(−0.63 to 0.59)) and FEV1% predicted (MD (95% CI)
−0.25 (−2.50 to 1.99)) was not significant. There was
no difference in sputum weight (MD (95% CI) −3.0
(−14.9 to 8.9)), patient perceived ease of clearance
(MD (95% CI) 0.4 (−0.6 to 1.3) or satisfaction (MD
(95% CI) 0.4 (−0.6 to 1.5)). The time taken for HTS
during ACT was significantly shorter (MD (95% CI)
14.7 (9.8 to 19.6)).
Conclusions: In this pilot study, HTS before ACT was
no more effective than HTS during ACT as measured
by LCI.
Trial registration number: NCT01753869;
Pre-results.
INTRODUCTION
There is clear evidence that airway clearance
techniques (ACT) to improve mucus clear-
ance should form part of treatment in cystic
ﬁbrosis (CF)1–4 and emerging evidence that
some forms of ACT may be more effective in
the long term.5 Quality of evidence in this
area is variable highlighting the need for
high-quality trials in the future to provide a
more robust evidence base for treatment.
Often, technique choice remains dependent
on patient preference and convenience as
well as age and stage of disease.5–7 Recent
research strategy has shifted from examining
the comparative efﬁcacy of different ACT to
the study of ways to optimise the application
of techniques.6 Finding the optimal treat-
ment for a patient at any speciﬁc time
requires consideration of available research
evidence on efﬁcacy among a range of other
factors including coordination with inhaled
therapies.8 Some forms of ACT now offer the
possibility to deliver inhaled therapies during
treatment and while these devices are attract-
ive in terms of reducing the time burden
associated with treatment, it is unclear how
the timing of inhaled therapies impact on
the effectiveness of ACT. Mucoactive agents
such as hypertonic saline (HTS) are recom-
mended to facilitate mucociliary clearance
based on clear evidence from high-quality
clinical trials across the age range and
KEY MESSAGES
▸ Optimal timing of treatment with hypertonic
saline (HTS) and airway clearance techniques
(ACT) is unknown.
▸ In this pilot study, HTS before ACT was no more
effective than HTS during ACT as measured by
Lung Clearance Index (LCI).
▸ LCI may not be a suitable short-term end point
for airways clearance trials as response is
unpredictable.
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disease trajectory in CF.9–14 These trials typically adminis-
tered HTS before ACT and this is currently the clinical
recommendation. Notably, some technologies to deliver
HTS during ACT were not available when these trials
were conducted and further studies of these methods
may yield useful results.
A recent Cochrane review highlighted how clinical
effect could be inﬂuenced by the timing of HTS delivery
in relation to ACT. The review outlined a number of
potential theoretical beneﬁts to inhalation of HTS
during airway clearance, including maximising the bene-
ﬁts of the immediate peak in the airway surface liquid
volume and reduced treatment time.15 Following this
review, a randomised controlled trial of 50 adult patients
with CF assessed the change in lung function (forced
expiratory volume in 1 second % (FEV1%) predicted)
and perceived effectiveness and satisfaction of three
treatment regimens (HTS before, during and after
ACT) at the end of a hospital admission.16 This study
found that effects on FEV1 were not signiﬁcant.
Satisfaction was rated signiﬁcantly worse when HTS was
inhaled after ACT compared with before or during ACT.
Perceived effectiveness of treatment showed similar
effects. The study concluded that people with CF should
be encouraged to time HTS before or during ACT to
maximise perceived efﬁcacy and satisfaction. There are
currently no data on the effect of HTS and ACT timing
on the Lung Clearance Index (LCI). LCI provides an
assessment of ventilation distribution as measured by
multiple-breath washout (MBW) which is increasingly
being used in CF interventional studies.17 It is estab-
lished that FEV1 lacks sufﬁcient sensitivity to detect
changes in the peripheral airways.18 LCI has shown
greater sensitivity to abnormalities in lung function com-
pared with spirometry across the age ranges in CF19 20
and has proven responsiveness in trials of inhaled ther-
apies21 22 and ACT23 in CF. Importantly, signiﬁcant
improvements in LCI have been reported with relatively
small numbers of patients (n=17–25).14 21 22 24 These
studies support the exploration of the effects of ACT in
CF using LCI.
This pilot study aimed to compare the change in LCI
at 90 min post treatment with HTS inhalation before
ACT compared with HTS inhalation during ACT in
adult patients with CF. Secondary outcomes included
the change in FEV1% predicted, forced expiratory ﬂow
(FEF)25–75% predicted, 24-hour sputum volumes,
patient-perceived and physiotherapist-perceived ease of
clearance and satisfaction with treatment, number of
coughs and duration of treatment.
METHOD
Subject recruitment
Inclusion criteria for the study were subjects with CF
aged ≥18 years, near the end of an intravenous anti-
biotic (IVAB) therapy course (days 10–14) for a pulmon-
ary exacerbation at Belfast Health and Social Care Trust
(BHSCT), who were productive of sputum ≥10 g over
24 hours on enrolment, currently use or had previously
used and tolerated HTS (Nebusal 7%) and provided
written informed consent. The exclusion criteria were
subjects who are HTS naive, had a reported intolerance
to HTS, currently participating in another study or have
participated in another study with an investigational
drug within 1 month of screening, or had a clinically sig-
niﬁcant condition other than CF or CF-related condi-
tions that could compromise the safety of the patient or
the quality of the data.
Subjects were recruited between December 2012 and
January 2015. This study was approved by the Ofﬁce for
Research Ethics Committees Northern Ireland (REC ref-
erence number 12/NI/0153), sponsored by Belfast
Health and Social Care Trust (reference number:
12025JB-AS) and registered with clinicaltrials.gov (refer-
ence number NCT01753869).
Treatment
Subjects were randomised to complete crossover treat-
ment of HTS before ACT inhalation (treatment order
A) and HTS inhalation during ACT (treatment order B)
on consecutive days. The ACT chosen was the Acapella
(Acapella Duet Vibratory PEP Therapy System, Portex,
Smiths Medical) which allowed for HTS inhalation
during treatment. Both subjects who were Acapella naive
and subjects who had previous experience of using
Acapella were included. Randomisation was electronic-
ally generated and concealed by an administrator inde-
pendent of the study. Treatment was assigned and
carried out by a qualiﬁed respiratory physiotherapist
(FM, JMB, KMcD). Full details for each treatment order
are presented in table 1. The assessor conducting the
outcome measures (KO’N) was blinded to the treatment
intervention order.
OUTCOME MEASURES
Lung Clearance Index
The MBW test to measure LCI was carried out using the
modiﬁed Innocor device and 0.2% sulfur hexaﬂuoride
(SF6) using the previously validated open-circuit tech-
nique in accordance with the standard operating pro-
cedure (see online supplement 2).25 Subjects breathed
through a mouthpiece at normal tidal volumes, while in
a seated position and wearing a nose clip. Analysis of
MBW data was performed using the Simple Washout
Programme (permission granted). Functional residual
capacity (FRC) was calculated as part of the LCI equa-
tion (LCI= cumulative expired volume/FRC). LCI repre-
sents the number of FRC lung volume turnovers it takes
to clear the inert gas (SF6) from the lungs and quanti-
ﬁes the degree of uneven gas mixing throughout the
lungs. MBW was performed before, immediately after
and 90 min after the treatment intervention. Ninety
minutes was considered the longest period that was rea-
sonable for a subject to wait. MBW was carried out
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either before or at least 30 min after spirometry in order
to avoid any effects of forced breathing manoeuvre on
LCI.
Spirometry
Spirometry was measured according to American
Thoracic Society/European Respiratory Society (ATS)/
(ERS) guidelines26 using a Microlab (ML3500 MK8)
spirometer (CareFusion, Kent, UK). FEV1% predicted
and FEF35-75% predicted values were calculated from ref-
erence ranges for all ages.27
Sputum wet weight
Wet-weight sputum (g) expectorated immediately after
each treatment session and total wet-weight sputum
expectorated in the 24 hours following the start of each
study visit was collected in preweighed containers and
recorded (Metter J Balance, Meter-Toledo, Switzerland).
Patient-perceived and physiotherapist-perceived ease of
clearance and satisfaction
Subjects and the physiotherapist delivering the treat-
ment intervention scored their perceived ease of
sputum clearance and level of satisfaction with each
treatment using a Visual Analogue Scale labelled not
easy/not satisﬁed and extremely easy/extremely satis-
ﬁed) (see online supplement 3).
Cough count
During each treatment session, the physiotherapist per-
formed a manual ‘cough count’ recording the number
of coughs per treatment session.
Statistical analysis
For the primary end point of change in LCI at 90 min
post treatment, a sample size of n=31 was estimated to
detect a treatment effect size of 1.5 assuming a signiﬁ-
cance level of 5% and a power of 80%. An interim ana-
lysis was planned at the halfway point. Data were
summarised using mean (SD) or median (IQR) statistics
as appropriate. Wilcoxon test and McNemar’s test were
used to assess change in the variables of interest. Mean
difference (MD) and 95% CIs were reported. Treatment
effect size was calculated as z/square root of N (number
of observations). Correlations were assessed using the
Spearman’s rho correlation coefﬁcient. A p value <0.05
was considered statistically signiﬁcant.
RESULTS
Following an interim analysis to compare change in LCI
at 1% α in data from 13 subjects, results showed the
treatment effect was unlikely to be sufﬁciently large to
attain clinical or statistical signiﬁcance. Given this and
challenges with recruitment, the decision was made to
terminate the study at this point. These study results are
presented as pilot data to inform future studies.
Fourteen subjects were recruited and 13 completed
the study. Figure 1 illustrates the ﬂow chart of recruit-
ment. Table 2 presents subject baseline characteristics.
Within-treatment change
The change in LCI from baseline to 90 min post treatment
with HTS before ACT (MD (95% CI) 0.10 (−0.59 to
0.79)) or with HTS during ACT (MD (95% CI) 0.12
(−0.42 to 0.66)) was not signiﬁcant (table 3 and ﬁgure 2A,
B). The FRC (component of the LCI) was signiﬁcantly
reduced with HTS during ACT treatment (MD (95% CI)
−0.11 (0.20 to 0.03)), but was unchanged with HTS before
ACT treatment (MD (95% CI) −0.55 (−0.17 to 0.06)).
With ACT after HTS, 8/13 patients worsened (ie, LCI
increased) and 5/13 patients improved (ie, LCI
decreased). With HTS during ACT, 7/13 worsened (ie,
LCI increased) and 6/13 improved (ie, LCI decreased).
Change in LCI from baseline to immediately after treat-
ment with HTS before ACT (MD (95% CI) −0.10 (−0.49
to 0.27)) or with HTS during ACT (MD (95% CI) 0.08
(−0.69 to 0.84)) was also not signiﬁcant (data not shown).
Considering the secondary outcome measures, the
change in FEV1% predicted (after 90 min) with HTS
before ACT was not signiﬁcant (MD (95% CI) 1.38
(−0.61 to 3.38)) 10/13 improved (ie, FEV1 increased),
2/13 worsened (ie, FEV1 decreased) and 1/13 stayed
the same. There was also no signiﬁcant change with
HTS during ACT (MD (95% CI) 1.64 (−1.06 to 4.34));
7/13 patients improved (ie, FEV1 increased), 4/13
Table 1 Treatment order details
Treatment order Detail
Treatment order A:
HTS before ACT
▸ Bronchodilator (Salbutamol
200 mcg);
▸ Wait 15 min;
▸ Single inhalation (4 mL) of 7%
HTS (Nebusal) via updraft
nebuliser (Portex) (∼20 min);
▸ Immediately followed by an
airways clearance session of 10
supervised cycles using the
Acapella and forced expiration
techniques (∼20 min).
Treatment order B:
HTS during ACT
▸ Bronchodilator (Salbutamol
200 mcg);
▸ Wait 15 min;
▸ Single inhalation (4 mL) of 7%
HTS (Nebusal) through the
Acapella Duet (with Portex updraft
nebuliser attached) device;
▸ During inhalation, an airways
clearance session of 10
supervised cycles using the
Acapella and forced expiration
techniques was carried out
(∼20 min).
Detailed content of the supervised cycles using the Acapella is
provided in online supplement 1. Subjects received the treatments
at the same time each day, in the same position (high sitting) and
the treatment duration was recorded.
ACT, airway clearance treatment; HTS, hypertonic saline.
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worsened (ie, FEV1 decreased) and 2/13 stayed the
same (table 3 and e-ﬁgure 1b). There was also no signiﬁ-
cant change in FEF35-75% predicted with either treat-
ment (table 3 and e-ﬁgures 2 a and b).
Between-treatment change
Comparing the two treatments (HTS before ACT vs
HTS during ACT), the change from baseline to immedi-
ately post treatment in LCI (MD (95% CI) −0.05 (−1.10
to 1.00)) and the change from baseline to 90 min post
treatment in LCI (MD (95% CI) −0.02 (−0.63 to 0.59)),
FEV1% predicted (MD (95% CI) −0.25 (−2.50 to 1.99))
and FEF35-75% predicted (MD (95% CI) −1.92 (−6.28 to
2.43)) was not signiﬁcantly different.
With both treatment orders, the change in LCI and
change in FEV1% predicted at 90 min post treatment
was not always in agreement. With HTS before ACT, LCI
and FEV1% predicted results were in agreement in 7/13
subjects (54%) (r=−0.51; p=0.08). With HTS during
ACT, LCI and FEV1 results were in agreement in 10/13
(77%) subjects (r=−0.48; p=0.10).
Comparing the two treatments (HTS before ACT vs
HTS during ACT) using the other study end points,
there was no difference in sputum weight expectorated
immediately post (MD (95% CI) −3.0 (−14.9 to 8.9)) or
24 hours post treatment (MD (95% CI) 77.4 (86.1 to
241.0)), patient-perceived ease of clearance (MD (95%
CI) 0.4 (−0.6 to 1.3)) or satisfaction (MD (95% CI) 0.4
(−0.6 to 1.5)). There was also no difference in the
Figure 1 Flow chart of recruitment.
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physiotherapist perception of the ease of clearance (MD
(95% CI) 0.7 (−0.2 to 1.6)), physiotherapist perception
of the satisfaction with treatment (MD (95% CI) −0.4
(−0.6 to 1.3)) or in the number of coughs recorded
between treatments (MD (95% CI) 6.2 (−0.02 to 12.5)).
The time taken for HTS during ACT was signiﬁcantly
shorter (MD (95% CI) 14.7 (9.8 to 19.6)) (e-table 1).
DISCUSSION AND CONCLUSIONS
As technology advances, more efﬁcient ways of deliver-
ing inhaled therapies linked to ACT are being explored
in an effort to reduce the treatment time required. This
pilot study aimed to explore the effectiveness of one
such strategy, HTS during ACT using the Acapella Duet.
This pilot study found that the timing of HTS in rela-
tion to ACT did not have a signiﬁcant effect on the
change in LCI after a single treatment session. Although
HTS during ACT was signiﬁcantly shorter in duration,
secondary end points of spirometry, sputum volumes,
patient and physiotherapist perception of ease and satis-
faction, and number of coughs were also not signiﬁ-
cantly different between treatments.
These results are in agreement with the ﬁndings by
Dentice and colleagues,16 who found no difference in
lung function between regimens (HTS before, during or
after ACT) and reported similar numbers of patients
stating a preference for ACT after or during HTS, com-
pared with ACT before HTS. The authors concluded
that preference for HTS before or during ACT over HTS
after ACT, could have implications for long-term adher-
ence. The pilot data presented in this paper adds to this
topic further exploring differences between HTS before
or during ACT regimens. Results suggest that if length of
treatment time is an issue affecting adherence, HTS
during ACT may offer a regimen which is equally effect-
ive but of shorter duration. Furthermore, although not
statistically signiﬁcant, notably fewer coughs were
required to expectorate the same volume of sputum
with ACT during HTS treatment compared with the
HTS before ACT treatment.
Importantly, these results indicate that as a novel end
point, LCI did not offer any further information in
response to ACT and HTS treatment compared with spir-
ometry. FEV1 is not always a suitable outcome measure
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Table 2 Subject baseline characteristics (n=13)
Baseline characteristics
Age (years) 33.2 (12.2)
Female/male 5:8
Median (IQR) 24-hour sputum weight (g) 20.0 (25.0)
FEV1% predicted 51.1 (22.0)
Median (IQR) FEF25-75% predicted 14.0 (38.0)
LCI (no. turnovers) 13.9 (3.7)
Mean (SD) unless otherwise stated.
FEF25–75% predicted, forced expiratory flow 25–75; FEV1
predicted, forced expiratory volume in 1 s; LCI, Lung Clearance
Index.
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for ACT trials due to its lack of sensitivity as an end
point.28 LCI was chosen as the primary outcome measure
in this study as it has demonstrated superior sensitivity to
changes in disease compared with spirometry20 and has
proven responsiveness to treatment effect with inhaled
therapies14 21 22 and ACT23 in CF. However, in this study,
LCI did not detect any change within or between treat-
ments. Change in LCI also did not signiﬁcantly correlate
with FEV1, with either treatment. Studies by Fuchs and
colleagues29 and Pﬂeger and colleagues30 have also
reported small and inconsistent changes (increasing and
decreasing) in LCI after physiotherapy with weak to
modest correlations between change in LCI and FEV1.
Results from this pilot study of patients primarily with
moderate to severe lung disease, add to this data provid-
ing results from two time points (immediately post and
90 min post treatment) from a clearly deﬁned interven-
tion (inhaled therapy and ACT). The change in FRC as a
component of LCI with HTS during ACT treatment was
signiﬁcantly decreased, but this did not translate to a
change in LCI. These results suggest that the effects of
sputum clearance on LCI and FRC are complex, as ACT
may open previously completely obstructed airways result-
ing in the recruitment of lung units paradoxically increas-
ing LCI. LCI may also be much less informative in those
with signiﬁcant airﬂow obstruction31 32 which made up a
large proportion of patients in this study (8/13 FEV1
<50% predicted at baseline). Discordant results with LCI
and FEV1 may not be surprising as they each measure a
different aspect of lung physiology. These results add to
the argument that LCI may not be a suitable short-term
end point for airways clearance trials as response is
unpredictable. Previous studies reporting signiﬁcant
effects assessed treatment effect were not short term but
over a period 4–48 weeks with inhaled therapies14 21 22
and 3 months with airways clearance therapy.23 Lack of
overall change in LCI in this study was in agreement with
other end points including spirometry, sputum weight
and patient preference supporting the validity of these
results. The mean change in FEV1 from baseline to
90 min post treatment (with HTS before ACT) could not
be considered clinically signiﬁcant.
Wet-weight sputum was chosen as a secondary
outcome measure as it is feasible to perform. However,
we acknowledge the inherent limitations of this measure
as a clinical trial end point. Expectorated wet-weight
sputum can include saliva, introducing error. An
increase of decrease in sputum can be interpreted as an
improvement, that is, an increase may mean improve-
ment in clearance or a decrease may mean a resolution
in infection. These issues limit the use of sputum as a
reliable trial end point, although it remains an end
point that is meaningful to patients.
In this study, inpatients receiving IVAB for treatment
of a pulmonary exacerbation were the target group for
recruitment. This was for feasibility reasons as the study
design involved treatment on two consecutive days which
would likely have been prohibitive for outpatients.
Although our study design aimed to ensure participants
were as close to their stable status as possible (days 10–
14 IVAB), our recruitment process demonstrated how
some patients were still unwell at this time point (ie, two
patients failed screening as they felt too unwell to
proceed; ﬁgure 1) and we cannot completely rule out
the effect of pulmonary exacerbation on the variability
of lung function results.31 However, this study represents
a ‘real-life’ evaluation of a treatment that is often carried
out during hospital admission.
This study investigated the use of a less commonly
used adjunct (Acapella Duet) through which to deliver
HTS during ACT. Using this device, we did not observe
any signiﬁcant deposition of HTS directly in the device
and the resistance levels achieved remained optimum
(between 10 and 20 cmH2O) in both treatments.
Figure 2 Change in LCI with (A) HTS before ACT and (B) HTS during ACT (mean and 95% CIs). ACT, airway clearance
treatment; HTS, hypertonic saline; LCI, Lung Clearance Index.
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Limitations of this study include the small sample size
and ﬁndings need to be reproduced in a larger sample,
therefore the conclusions must be interpreted with
caution. Recruitment was challenging due to inclusion
criteria in the study which required that subjects had
previously taken and tolerated HTS and be productive
of ≥10 g of sputum at the end of IVAB treatment. Of the
subjects who met the criteria, the majority progressed to
screening (20/32; 63%) and thereafter randomisation
(14/20; 70%). Opening the study to outpatients could
have increased the number of potentially eligible
patients; however, adherence to the study design (attend-
ance on two consecutive days), we believe, would have
been challenging.
This pilot study is the ﬁrst study to assess the effect of
HTS and ACT timing using LCI as an outcome measure
and employed rigorous study design including blinded
outcome measure assessor and a broad range of
measures.
Overall, the results from this pilot study could not
support the hypothesis that HTS before ACT was more
effective than HTS during ACT as measured by LCI.
Results indicate that HTS during ACT was no more
effective than HTS before ACT, although it did result in
a shorter treatment duration.
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